Evaluating immune responses to pneumococcal vaccines
Open Access
- 7 September 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (3) , 127-131
Abstract
Streptococcus pneumoniae (pneumococcus) is a significant cause of bacterial infections ranging from mild infections affecting the respiratory tract such as otitis media and sinusitis to severe diseases including bacteremia, pneumonia, and invasive pneumococcal disease (IPD) (eg, meningitis, septic arthritis, and endocarditis). Pneumococcal vaccines were first developed in the 1970s as capsular pneumococcal polysaccharide vaccines, which were T-cell independent and hence lacked immunologic memory. Subsequently in the year 2000, pneumococcal conjugate vaccines (PCV) conjugated to a protein to increase immunogenicity were developed and made commercially available. The increasing number of pneumococcal serotypes identified and the expanding pipeline of PCV vaccines with improved immunogenicity have significantly reduced the morbidity and mortality associated with IPD in high-risk patients. Pneumococcal vaccines also play an important role in the diagnosis and immunophenotyping of children and adults with inborn errors of immunity (IEI) given the increasing diversity/heterogeneity of IEI presenting with primary and/or specific antibody deficiency. Other than the quantitation of serotype levels in routine clinical care, other measurements of immune response including the functional activity of antibodies, antibody avidity, cell-mediated immunity, and immunological memory remain limited to clinical trials during vaccine development.Keywords
This publication has 35 references indexed in Scilit:
- Anaphylaxis to pneumococcal vaccine; CRM(197): Novel cause of vaccine allergyPediatric Allergy and Immunology, 2016
- Practice parameter for the diagnosis and management of primary immunodeficiencyJournal of Allergy and Clinical Immunology, 2015
- Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR. Morbidity and Mortality Weekly Report, 2015
- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)2014
- Pneumococcal infection in adults: burden of diseaseClinical Microbiology and Infection, 2014
- Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in childrenVaccine, 2013
- Anaphylaxis to the 23-valent pneumococcal vaccine: A second explored case by means of immediate-reading skin tests with pneumococcal vaccinesVaccine, 2010
- Rare Systemic Dermatologic Reaction after Pneumococcal Vaccine AdministrationSouthern Medical Journal, 2003
- Anaphylaxis to the 23-valent pneumococcal vaccine in child: a case-control study based on immediate responses in skin tests and specific IgE determinationVaccine, 2001
- Leukocytoclastic vasculitis after pneumococcal vaccinationAmerican Journal of Infection Control, 1998